Home/Pipeline/TLX101 (Pixclara® / 131I-IPA)

TLX101 (Pixclara® / 131I-IPA)

Glioblastoma (GBM)

Phase 3Active (IPAX-2)

Key Facts

Indication

Glioblastoma (GBM)

Phase

Phase 3

Status

Active (IPAX-2)

Company

Telix Pharmaceuticals

About Telix Pharmaceuticals

Telix Pharmaceuticals is a commercial-stage leader in the theranostic radiopharmaceutical space, with a mission to deliver precision medicine through targeted radiation. Its strategy is validated by the successful global commercialization of its FDA-approved prostate cancer imaging agent, Illuccix®, which funds and de-risks a broad, late-stage pipeline of therapeutic candidates. The company is executing a vertically integrated model, combining therapeutic development with precision diagnostics, medtech, and a global manufacturing network to capture value across the cancer care continuum.

View full company profile

Therapeutic Areas

Oncology Rare Diseases

Other Glioblastoma (GBM) Drugs

Drug	Company	Phase	Status
DB102 (Enzastaurin)	Denovo Biopharma	Phase 3	Active
GlioGuard Therapeutic & Diagnostic System	GlioGuard	Pre-clinical	Active
DOC1021	Diakonos Oncology	Phase 2	Active
Lead CAR-T Program	Kiragen Bio	Pre-clinical	Active
GBM Immunotherapy (with SandboxAQ)	iOncologi	Pre-clinical	Active
DCVax®-L	Northwest Biotherapeutics	Phase 3	Active
Lucicebtide (ST101)	Sapience Therapeutics	Phase 2	Active
TLR-AD1	NovAccess Global	Pre-clinical	Active
Glioblastoma Assay Optimization (CPRIT Grant)	SingleCell Biotechnology	Pre-clinical	Active
Lead Program (unspecified)	BlueHaven Therapeutics	Preclinical	Active
Paxalisib	Kazia Therapeutics	Phase II/III	Active